Background-T-wave alternans (TWA) has been implicated in the pathogenesis of ventricular arrhythmias and sudden cardiac death. However, to estimate and suppress TWA effectively, the phase of TWA must be accurately determined. Methods and Results-We developed a method that computes the beat-by-beat integral of the T-wave morphology, over time points within the T-wave with positive alternans. Then, we estimated the signed derivative of the T-wave integral sequence, which allows the classification of each beat to a binary phase index. In animal studies, we found that this method was able to accurately identify the T-wave phase in artificially induced alternans (P<0.0001). The coherence of the phase increased consistently after acute ischemia induction in all body-surface and intracardiac leads (P<0.0001). Also, we developed a phase-resetting detection algorithm that enhances the diagnostic utility of TWA. We further established an algorithm that uses the phase of TWA to deliver appropriate polarity-pacing pulses (all interventions compared with baseline, P<0.0001 for alternans voltage; P<0.0001 for K score ), to suppress TWA. Finally, we demonstrated that using the phase of TWA we can suppress spontaneous TWA during acute ischemia; 77.6% for alternans voltage (P<0.0001) and 92.5% for K score (P<0.0001). Conclusions-We developed a method to quantify the temporal variability of the TWA phase. This method is expected to enhance the utility of TWA in predicting ventricular arrhythmias and sudden cardiac death and raises the possibility of using upstream therapies to abort a ventricular tachyarrhythmia before its onset. 
T -wave alternans (TWA) testing has been associated with an increased risk for ventricular tachyarrhythmic events, such as ventricular tachycardia (VT), ventricular fibrillation (VF), and sudden cardiac death (SCD), 1 during medium-and long-term follow-up.
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However, beyond medium-and long-term risk prediction, several lines of preclinical and clinical evidence suggest that the presence of heightened TWA may play a more proximal role in creating the substrate necessary for malignant ventricular arrhythmias. [4] [5] [6] Analysis of intracardiac electrograms from implantable cardioverter-defibrillator leads has demonstrated a sharp increase in TWA magnitude immediately before spontaneous ventricular arrhythmias, [7] [8] [9] without a similar upsurge in TWA before induced ventricular arrhythmias or preceding inappropriate implantable cardioverter-defibrillator shocks. 7 Simultaneous measurement of TWA from body-surface and intracardiac electrograms by our group 10 and others 11 has
shown a high degree of correlation, suggesting that these measurements are detecting the same electric phenomenon. In aggregate, the clinical and experimental data suggest that the heart either passes through a state of heightened TWA on the way to VT and VF, or heightened TWA occurs in close conjunction with developing ventricular tachyarrhythmic events. 12, 13 In either scenario, these findings suggest that detecting significantly elevated levels of TWA may serve as an important short-term predictor of impending arrhythmias and also raise the possibility for a therapeutic role where TWA suppression therapies are delivered upstream to suppress the arrhythmogenic substrate and abort VT/VF prior to the arrhythmia onset. 2, 14 The clinical application of TWA, whether it serves a diagnostic role for medium-and long-term risk prediction or a therapeutic role for guiding short-term upstream antiarrhythmic therapy, requires the ability to estimate TWA accurately. It has been reported that abnormal beats with altered morphology or timing present inherent difficulties in the estimation of alternans, 15 primarily by provoking changes in TWA phase. 16 However, assessment of the alternans phase, a term that refers to the specific phase of an alternating sequence of long and short or large and small T-waves, has generally been underappreciated in clinical TWA testing. Current algorithms used to estimate TWA classify premature ventricular contractions (PVCs) and beats following transient prolongation or shortening of the cycle length as bad beats, but they do not estimate the phase of TWA either preceding or following such bad beats. However, a bad beat may cause phase resetting of TWA and therefore may either reduce the amplitude of alternans 15 or potentiate the amplitude of alternans. 16 In either case, PVCs may significantly hamper the TWA estimation by generating a false-positive or a false-negative result. Therefore, the development of methods to estimate the phase of TWA before and after a bad beat, and consequently account for changes in phase, may significantly improve the performance of TWA as a diagnostic test for predicting medium-and long-term arrhythmia risk. 17, 18 Similarly, the ability to estimate the phase of TWA is also likely to have a critical impact on designing potential therapeutic strategies to suppress TWA and mitigate short-term arrhythmia risk. However, as has been demonstrated, 2 lack of a priori knowledge of the phase of TWA (long and short or large and small T-waves) may increase the amplitude of alternans and potentiate, rather than suppress, the arrhythmogenic substrate. Therefore, developing methods to estimate the phase of alternans in real time is likely to play an important role in designing therapies to suppress TWA.
In this study, we aim to examine the hypothesis that algorithms to estimate the phase of TWA in intracardiac and bodysurface signals can improve the diagnostic and therapeutic use of TWA.
Methods
Animal Preparation
Twenty-four male Yorkshire swine (40-45 kg) were anesthetized and acutely instrumented in the Animal Electrophysiology Laboratory of the Massachusetts General Hospital. The protocol was approved by the Animal Care and Use Committee of the Hospital.
Anesthesia was induced with Telazol (4.4 mg/kg) IM and Xylazine (2.2 mg/kg) IM. Each subject was intubated and placed on a mechanical ventilator, and anesthesia was maintained with Isoflurane (1.5% to 5%).
Standard electrocardiographic electrodes were placed on the subject's limbs and chest; the epidermis was excised at point of contact to maximize signal quality. An arterial line was used to monitor arterial blood pressure. Percutaneous intracardiac access was achieved in the jugular veins and femoral arteries and veins by using standard Seldinger techniques. Decapolar catheters were placed under fluoroscopic guidance (1) in the right ventricle (RV), the distal lead being at the RV apex, (2) in the coronary sinus (CS), the distal lead being at the distal CS, and (3) in the left ventricle (LV), the proximal lead being at the LV apex. An inferior vena cava catheter was inserted as a reference electrode for unipolar signals.
Regional myocardial ischemia was induced in 11 subjects via balloon occlusion of the proximal left circumflex coronary artery by using standard percutaneous cardiac catheterization techniques.
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Equipment and Data Collection Methods
Intracardiac and body-surface (leads II and V4) electrocardiographic signals as well as arterial blood pressure were recorded through a Prucka Cardiolab (General Electric) electrophysiology system that provided 16 high fidelity analog output signals, as previously described. 10, 14 We used a previously developed signal acquisition, analysis, and display system, consisting of custom software written in LabView 8.5 (National Instruments, Austin, TX) and MATLAB 7.6 (MathWorks Inc, Natick, MA). 10 Details of the alternans estimation algorithm 10, 14 are provided in the online-only Data Supplement. TWA estimates were obtained from 2 body-surface leads and 12 intracardiac unipolar leads (3 in each of the RV, LV, and CS catheters).
We have used a programmable stimulator that is capable of dynamically delivering pacing pulses on a beat-to-beat basis. Each pacing pulse is triggered upon detection of an ECG waveform (the R-wave).
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TWA Phase Estimation
The algorithm we developed to estimate the phase of TWA is presented in Figure 1A , and is described below. To compute a phase index (PI) that differentiates between the 2 phases of TWA ( Figure 1B ), we devised a method that is based on the integral of the T-wave. The method relies on computing the beat-by-beat integral of the T-wave morphology ( Figure 1C ) between the onset and offset T-wave points (as determined by the wavelet transform).
To maximize the effect of T-wave samples with significant alternans on the integral value and at the same time to account for the temporal characteristics of the TWA, we estimated the alternans voltage and K score 8,10 on a point-by-point basis throughout the T-wave, using a rolling 128-beat window that was shifted 1 beat at a time. Then, the integral was calculated at each time point within the T-wave with statistically significant TWA (ie, points with K score >3 and alternans voltage greater than a lead-dependent threshold) 10 and normalized to the number of points used for the integral estimation. This improved integral provides a more accurate means of determining the phase of the alternating T-waves.
To overcome subtle changes in the beat-to-beat T-wave morphology that may affect the phase estimation, we introduced the signed derivative of the T-wave integral that allows the classification of each beat to a binary PI that takes 2 different values: +1 or −1 corresponding to large or small integral values, respectively ( Figure 1D) .
Finally, to minimize the sensitivity of the algorithm to an arbitrary ECG reference channel, we have devised an artificial alternating reference phase index sequence (+1,−1,+1,−1,…) against which the phase time series of each lead is compared.
To investigate the degree of synchronous alternation between 2 waveforms quantitatively, the coherence of 2 signals (estimated phase and reference phase) has been estimated using the Welch's averaged periodogram method (for more information, please see the onlineonly Data Supplement).
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Statistical Methods
Aggregate variables were expressed as mean±SD. Box-plot representation including the median, 90% to 10%, and 95% to 5% percentiles was used to demonstrate statistical properties of the estimated coherence in data sequences with and without repolarization alternans. For each channel, coherence values were compared before and after R-wave-triggered pacing by using the Wilcoxon signed-rank test. The phase of TWA was compared across catheters by using the Kruskal-Wallis ANOVA. Comparisons between alternans voltage and K score across leads before and after R-wave-triggered pacing used 2-way ANOVA. The 95% confidence intervals for sensitivity, specificity, positive predictive value, negative predictive value, and accuracy were calculated based on binomial distribution. A P<0.05 was used to determine statistical significance. Statistical analysis was performed using MATLAB (MathWorks Inc, Natick, MA) and STATA (StataCorp LP, College Station, TX).
Results
Evaluation of the Estimation of the TWA Phase in the Normal Heart
We evaluated the ability of the algorithm to estimate the phase of TWA accurately by using R-wave-triggered pacing during the absolute refractory period. Pacing pulses of (1) amplitude: ±1 and ±5 mA, (2) width: 30 ms, and (3) coupling to the R-wave: 10 ms were delivered during the absolute refractory period on every-other-beat basis from 2 leads (RV12) of a decapolar catheter, at the apex of the RV, to modulate ventricular repolarization and induce TWA.
To investigate the ability of our algorithm to determine the phase of the T-wave, we estimated the PI at baseline and after R-wave-triggered pacing. We then evaluated the coherence at 0.5 cycles/beat between the artificial alternating reference PI sequence and the PI series for each of the leads at the body-surface and CS, LV, and RV catheters, before and after R-wave-triggered pacing. For each K score and alternans voltage, TWA was considered positive if K score >3 and alternans voltage were greater than the lead-specific thresholds (bodysurface, 0.55 µV; CS, 1.98 µV; LV, 4.18 µV; RV, 4.235 µV).
10
The box-plot representation of the phase coherence distributions for sequences of negative and positive alternans during all 4 pacing protocols is shown in Figure 2A for body-surface and intracardiac leads. The summary statistics demonstrate that the coherence is significantly higher for positive alternans than negative alternans across all leads on the body-surface and intracardiac leads (P<0.0001 for all paired comparisons; n=36 for each of the body-surface, CS, LV, and RV leads, where n represents the overall sample size: 9 subjects for each of the ±1 and ±5 mA pacing interventions). in the normal heart (n=9) for negative and positive alternans sequences. A, Box-plot representation of the estimated coherence value at 0.5 cycle/beat for negative alternans (white boxes) and positive alternans (gray boxes) during baseline and after R-wave-triggered pacing for body-surface, coronary sinus (CS), left ventricle (LV), and right ventricle (RV) leads. For each set of body-surface leads and intracardiac leads, the median (horizontal solid line), 90% to 10% percentiles (box), and 95% to 5% percentiles (error bars) are shown. The dashed lines indicate the lead-dependent coherence threshold determined using the corresponding receiver-operating characteristic (ROC) curve (n=36 for each of the body-surface, CS, LV, and RV leads; where, n represents the overall sample size: 9 subjects for each of the ±1 and ±5 mA pacing interventions). B, Sensitivity (Sn) and specificity (Sp) for body-surface and intracardiac leads as a function of their respected coherence threshold. C, ROC curves for bodysurface leads and intracardiac leads determined by changing the coherence threshold from 0 to 1 in steps of 0.001. For each lead, statistically significant comparisons (negative alternans vs positive alternans) are marked by an asterisk.
Then, to estimate the phase coherence thresholds for bodysurface and intracardiac leads, we estimated the receiver-operating characteristic curve for coherence values ranging from 0 to 1 and computed the true and false detection rates for positive and negative alternans by using the coherence values, as follows. By using the TWA criteria described above (for K score and alternans voltage), the estimated coherence indicated a true-positive or false-negative outcome if it was greater or smaller than the corresponding threshold. Similarly, if alternans was negative, the coherence estimate was considered a false-positive or true-negative depending on whether its value was greater or smaller than the corresponding threshold.
In Figure 2B , we plot the sensitivity (Sn) and specificity (Sp) for body-surface and intracardiac leads as a function of coherence threshold. The corresponding receiver-operating characteristic curves are shown in Figure 2C . The area under the curve for body-surface leads and intracardiac CS, LV, and RV catheters was 0.99, 0.95, 0.98, and 0.99, respectively. For each lead configuration, the optimal phase coherence threshold was determined as the point that has the minimum distance to the point (Sn,1−Sp)=(1,0), which is equal to minimizing Figure 2C ). The estimated thresholds for body-surface, CS, LV, and RV leads were 0.419, 0.376, 0.406, and 0.647, respectively. These thresholds are shown by the horizontal lines in Figure 2A 
Evaluation of the Estimation of the TWA Phase in the Presence of Acute Ischemia
To investigate the ability to estimate the phase of spontaneous TWA, we applied our algorithm on body-surface and intracardiac (CS, LV, and RV leads) electrograms recorded before (baseline) and during acute ischemia. The number of beats per subject recorded before and during coronary artery occlusion was 848±334 and 954±532, respectively (P=0.69; signedrank=23; n=10). The mean heart rate at baseline and during coronary artery occlusion was 106.7±9.2 and 109.2±20.1 beats per minute, respectively (P=1; signed-rank=0; n=10).
The In Figure 3 , we summarized the compiled results (n=10) of the coherence distributions for electrograms recorded before and during acute ischemia. The coherence is significantly higher for ischemia-induced TWA than baseline across all leads on the body-surface and intracardiac leads (P<0.0001 for all paired comparisons; n=80, where n represents the total number of comparisons: 40 for baseline and 40 during ischemia, 10 for each of the body-surface, CS, LV, and RV leads). No statistically significant difference was observed as a function of lead type, including between body-surface and any of the intracardiac catheter leads (baseline: Kruskal-Wallis test, P=0.62, n=10; post-balloon occlusion: Kruskal-Wallis test, P=0.88; n=10, where n is the number of study subjects used in this comparison). These results suggest that an increase of the TWA magnitude during acute ischemia is associated with an increase of the corresponding coherence, while as expected during baseline when TWA was deemed negative, the associated coherence values were significantly lower.
To evaluate the performance of the algorithm to estimate the phase in the presence of myocardial ischemia, we applied the previously receiver-operating characteristic-derived phase coherence thresholds to the results reported in Figure 3 ( Table) . We observe that the accuracy of the estimation for bodysurface, CS, LV, and RV leads is 0.91, 0.94, 0.93, and 0.90, respectively. These results suggest that coherence thresholds estimated from artificially induced alternans can be applied to the acute ischemia model and yield highly accurate estimates of the TWA phase in both body-surface and intracardiac leads.
Detection of TWA Phase Resetting
Having examined the ability of the proposed method to estimate the phase of TWA, we evaluated the use of the PI as a means to detect phase resetting (Figure 4) . To detect potential TWA phase resetting, we estimated the cross-correlation of the estimated TWA phase with that of the reference PI sequence, which at the point of phase resetting is expected to result in a zero-crossing and a change in the polarity of the correlation coefficient (online-only Data Supplement).
In Figure 4A -4D, we demonstrate the performance of the proposed phase-resetting detection algorithm in 2 different study subjects in body-surface electrograms recorded during myocardial infarction. The first subject shows a reduction of the alternans voltage and K score caused by phase resetting from a PVC at beat numbers 628 and 831 (lead V4). The second subject shows an artificial increase of the alternans voltage and K score caused by a PVC at beat number 350 (lead V4). Each of these 2 PVCs results in an abrupt decrease or increase in the estimated correlation of the phase of the signal with that of the reference channel, manifested by a zero-crossing of the correlation coefficient and changes in the sign of the correlation coefficient before and after the zero-crossing point.
We applied the phase-resetting detection algorithm to all 10 subjects during acute ischemia and found a total of 67 incidents of phase resetting out of 224 QRS-complex morphology changes (ie, PVCs), yielding a 30% probability of experiencing phase resetting when a bad beat occurs. This signifies the relatively high incidence of artificial modulation of TWA estimation, which can now be determined by the proposed phaseresetting detection algorithm.
Utility of the TWA Phase to Trigger Appropriate Electrical Therapy
After evaluating the ability of the proposed method to estimate the phase of artificially induced and spontaneously occurring TWA, we evaluated its performance as a means to guide electrical therapy aimed to suppress TWA.
Specifically, we used R-wave-triggered pacing pulses during the absolute refractory period to induce and suppress TWA from 2 catheter leads in the RV (induction lead, RV12; suppression lead, RV34 or RV56; pulse amplitude, ±7 mA; pulse width, 30 ms; coupling to R-wave, 30 ms). In Figure 5 , baseline (intervention A) corresponds to alternans induced during R-wave-triggered pacing from RV12 on an every-other-beat basis, whereas subsequent interventions refer to the effect of varying the R-wave-triggered stimulus polarity delivered from RV34 or RV56 with respect to the phase of alternans (induced from RV12). In interventions (B) to (E), R-wavetriggered pacing from RV12 continues on an every even beat basis; however, triggered stimuli are now delivered from RV34 or RV56 on every odd beat (B and C) or every even beat (D and E) with −7 mA (B and E) or +7 mA (C and D).
To establish a relationship between the outcome of the R-wave-triggered pacing with the pacing pulse polarity and the phase of TWA, we estimated the alternans voltage and K score using the protocol described above and reported the product of (pacing polarity)×(phase polarity). Phase polarity is defined as positive when the stimulus from RV34 or RV56 is triggered on beats with the opposite phase to the phase of alternans at baseline (out-of phase pacing). In contrast, phase polarity is defined as negative when the RV34 or RV56 stimulus is triggered on beats with the same phase as the phase of alternans at baseline (in-phase pacing). The alternans voltage and K score for body-surface, CS, LV, and RV leads for each of the above interventions are shown in Figure 5 (n=8) . We observe that in-phase pacing with negative pulse polarity, as well as outof phase pacing with positive pulse polarity, results in TWA increase, whereas in-phase pacing with positive pulse polarity or out-of phase pacing with negative pulse polarity results in a reduction of TWA (comparison between baseline and each of the interventions used to suppress alternans for each lead type: P<0.0001 for alternans voltage, P<0.0001 for K score for the same paired interventions; n=8).
These results demonstrate that lack of a priori knowledge of the phase of TWA may result in an increase in the TWA amplitude (as shown in interventions C and E). Therefore, to effectively suppress TWA, one needs to know the phase of the estimated TWA. Based on these results, we propose that when the alternans phase and pacing pulse have opposite polarity, R-wave-triggered pacing will decrease TWA.
Utility of the TWA Phase to Suppress Spontaneous TWA During Acute Ischemia
We have further evaluated the use of the phase-dependent R-wave-triggered pacing during the absolute refractory period to suppress spontaneous TWA in sinus rhythm, in vivo.
In Figure 6 , we plot the alternans voltage and K score of a triangular intracardiac bipolar lead configuration CS2CS8, CS2LV4, and CS2LV10 (an optimized intracardiac alternans detection lead system), 14 after coronary artery balloon occlusion. In intervention A, one observes significant spontaneously occurring TWA. Upon detection of significant TWA, we estimated the phase of TWA and applied in-phase R-wavetriggered pacing with positive polarity from a catheter lead in the RV apex with the following parameters: amplitude: +4 mA; pulse width: 10 ms; pulse coupling: 10 ms, on every even beat (intervention B). We observe that R-wave-triggered pacing results in a significant reduction of spontaneous TWA during acute ischemia (77.59% average reduction across the 3 leads of the alternans voltage compared with baseline, P<0.0001; 92.55% average reduction across the 3 leads of the K score compared with baseline, P<0.0001). In intervention C, RV12-triggered pacing is discontinued, leading to increase of the alternans voltage and K score (68.62% average increase across the 3 leads of the alternans voltage compared with TWA suppression, P<0.0001; 87.06% average increase across the 3 leads of the K score compared with TWA suppression, P<0.0001).
Incidentally, pacing on an every beat basis does not decrease the level of alternans (data not shown). This finding is further supported by our recent observation 14 that pacing during the absolute refractory period on every beat basis induces a consistent, lead-dependent modulation on ventricular repolarization. These data provide an important proof of concept that the phase of TWA is a critical parameter of TWA that can be estimated in real time and used to suppress spontaneously occurring TWA.
Discussion
In light of extensive preclinical 12, 13, [20] [21] [22] [23] and clinical data 8, 9, 11, 24 demonstrating an association between heightened TWA and the onset of malignant arrhythmias including VT and VF, the accurate detection and potential modulation of TWA may hold promise as a method to predict and preempt lethal heart rhythm disturbances. We have previously shown that a premature beat may alter the phase of alternans with significant implications on the estimation of TWA and its predictive use. 15 The main aim of this study was to establish a robust method to quantify the temporal variability of TWA phase and to use and K score (right) is shown for alternans baseline (through R-wave-triggered pacing on alternate beats from lead RV12) and after phase perturbation (through R-wave-triggered pacing from RV34 or RV56 leads) for body-surface, coronary sinus (CS), left ventricle (LV), and right ventricle (RV) leads (n=8). The pacing polarity and phase polarity for the interventions after the alternans baseline is shown on horizontal axis. For each intervention, the median (horizontal solid line), 90% to 10% percentiles (box), and 95% to 5% percentiles (error bars) are shown. Both alternans voltage and K score increased for interventions with positive (pacing polarity)×(phase polarity). In contrast, both alternans voltage and K score decreased for interventions with negative (pacing polarity)×(phase polarity).
it to enhance the medium-and long-term SCD risk prediction of TWA as well as to guide short-term electrical therapy to suppress TWA. This study is the first to provide a comprehensive and systematic approach to determine the phase of TWA in body-surface and intracardiac leads. Specifically, first we have shown that the method we have developed to estimate the phase of TWA is robust and sensitive to subtle changes of the T-wave morphology. Second, use of an artificial alternating reference PI sequence allows the real-time estimation of the temporal dynamics of the TWA phase. Third, during acute ischemia, the phase-derived coherence can discriminate between negative and positive TWA levels and provide highly accurate estimates of the TWA phase. Fourth, the phase-derived coherence can be used to determine phase-induced variability of TWA that results in significant improvement in the TWA estimation. Fifth, the phase of TWA and the polarity of a pacing pulse are sufficient to define a pacing strategy to suppress TWA in vivo. Sixth, we have been able to demonstrate that the TWA phase can be used to suppress spontaneously occurring TWA following acute myocardial infarction, in vivo.
Our results may have important clinical applications for diagnostic and therapeutic procedures that are based on TWA estimation. From a diagnostic point of view, microvolt TWA testing has emerged as an important predictor of SCD during medium-and long-term follow-up. 25, 26 However, although the negative predictive value of TWA testing has generally been good, the positive predictive value has been much less robust. 27 Our data suggest that methods to improve the positive and negative predictive value of TWA testing may significantly improve its predictive use. It has previously been shown that the presence of PVCs or other bad beats (with altered morphology and timing) may have a profound detrimental effect on TWA testing by either underestimating 15 or overestimating 16 the level of TWA. Our study extends these previous findings by demonstrating that PVCs frequently lead to modulation of TWA in a swine model of acute coronary ischemia. The presence of PVCs is very common during clinical TWA testing, and the presence of frequent PVCs is the most common reason for indeterminate test results. 10 Additionally, the likelihood of indeterminacy increases with progressively more impaired left ventricular systolic function, 26 suggesting that patients at highest risk of SCD may be particularly susceptible to false-positive or false-negative TWA results attributable to PVC-induced phase resetting. The algorithm developed and validated in this study may provide a robust method for detecting scenarios where phase reversals are likely to lead to false-positive or false-negative TWA estimates and thus may significantly improve the sensitivity and the positive and negative predictive values of TWA testing.
Furthermore, studies in humans in which TWA was measured during ventricular pacing have demonstrated that the A B C A B C Figure 6 . Utility of the T-wave alternans (TWA) phase to suppress spontaneously occurring alternans in sinus rhythm during acute myocardial ischemia. Alternans voltage and K score are plotted for the intracardiac lead configuration CS2CS8, CS2LV4, and CS2LV10. In-phase suppression pacing intervention is delivered from the right ventricle apex (RV12; amplitude: +4 mA, width: 10 ms, coupling to R-wave: 10 ms presence of alternans phase reversal after PVCs carries important prognostic information and predicts a significantly lower arrhythmia-free survival when compared with patients without post-PVC phase reversal. 28 However, extension of these findings has been limited by the lack of a validated method to measure the alternans phase in an efficient manner. Our data suggest that in addition to improving positive and negative predictive values, incorporating information about phase reversal into clinical TWA testing algorithms may independently improve the use of noninvasive TWA testing for medium-and long-term SCD risk prediction.
From a therapeutic perspective, several lines of preclinical and clinical evidence suggest that the presence of heightened TWA may play a causative or permissive role in creating an arrhythmogenic substrate and setting the stage for impending ventricular arrhythmias. 29 It has been suggested that appropriately timed pacing therapy, potentially delivered from an implantable device (eg, implantable cardioverter-defibrillator), may be capable of suppressing the amplitude of TWA and potentially pre-empting the onset of VT and VF. 2, 14 In order for such upstream therapies to be viable, several conditions must be met. First, TWA must be detectable from an implantable device in real time with a high degree of sensitivity and fidelity. In this regard, we have developed and validated a novel intracardiac lead configuration system which has been shown to be highly sensitive in capturing the spatiotemporal nature of intracardiac alternans. 10 Second, once a state of heightened TWA is detected, device-delivered therapy must be administered with the goal of rapidly suppressing the alternans magnitude and quelling the arrhythmogenic substrate. We have recently demonstrated that R-wave-triggered pacing pulses delivered during the absolute refractory period are capable of suppressing TWA. 2, 14 However, the outcome of R-wave-triggered pacing therapy is critically dependent on the alternans phase and if pacing therapy does not consider the TWA phase, the amplitude of TWA may be potentiated rather than suppressed. Therefore, being able to measure the TWA phase in real time and then to deliver customized therapy is a critical step in being able to suppress TWA reproducibly. In this study, we have demonstrated the importance of phase and pacing pulse polarity in determining the response to pacing therapy. Specifically, in-phase pacing with positive polarity pulses or out-of phase pacing with negative polarity pulses provides a consistent suppression effect on TWA. It is likely that TWA suppression helps reduce repolarization gradients and thus reduce arrhythmia susceptibility. The important relationships established in this article between phase polarity and response to R-wave-triggered therapy are likely to become a crucial step in designing future studies that specifically assess the effect of alternans suppression algorithms on arrhythmia inducibility with the aim of validating the concept of upstream therapy. However, it should be noted that acute ischemia-induced alternans and SCD may have a different physiology than chronic ischemic-related alternans and SCD.
Conclusions
Our findings support the idea that the temporal variability of the phase of TWA can be effectively estimated by analysis of subtle changes of the T-wave amplitude that occur on a beatto-beat basis. The algorithm presented in this study aims to enhance both the diagnostic and therapeutic clinical utility of TWA estimation.
